Proteasome inhibitors in medullary thyroid carcinoma: time to restart with clinical trials?

INTRODUCTION: Medullary thyroid cancer (MTC) is a rare thyroid tumour whose management in advanced stages is challenging, despite effective therapeutic options having expanded in recent years. Proteasome inhibitors (PrIn) have shown the ability to improve patient outcomes, including survival and qua...

Descripción completa

Detalles Bibliográficos
Autores principales: Fanciulli, Giuseppe, Modica, Roberta, La Salvia, Anna, Grossrubatscher, Erika Maria, Florio, Tullio, Ferraù, Francesco, Veresani, Alessandro, Russo, Flaminia, Colao, Annamaria, Faggiano, Antongiulio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157225/
https://www.ncbi.nlm.nih.gov/pubmed/37152939
http://dx.doi.org/10.3389/fendo.2023.1145926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157225/
https://www.ncbi.nlm.nih.gov/pubmed/37152939
http://dx.doi.org/10.3389/fendo.2023.1145926

Ejemplares similares